Items where Author is "Bar-Or, A."

2016

Kappos, L. and Arnold, D. L. and Bar-Or, A. and Camm, J. and Derfuss, T. and Kieseier, B. C. and Sprenger, T. and Greenough, K. and Ni, P. and Harada, T.. (2016) Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology, 15 (11). pp. 1148-1159.

2011

Probstel, A. K. and Dornmair, K. and Bittner, R. and Sperl, P. and Jenne, D. and Magalhaes, S. and Villalobos, A. and Breithaupt, C. and Weissert, R. and Jacob, U. and Krumbholz, M. and Kuempfel, T. and Blaschek, A. and Stark, W. and Gartner, J. and Pohl, D. and Rostasy, K. and Weber, F. and Forne, I. and Khademi, M. and Olsson, T. and Brilot, F. and Tantsis, E. and Dale, R. C. and Wekerle, H. and Hohlfeld, R. and Banwell, B. and Bar-Or, A. and Meinl, E. and Derfuss, T.. (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology, 77 (6). pp. 580-588.

Mehling, M. and Johnson, T. A. and Antel, J. and Kappos, L. and Bar-Or, A.. (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology, Vol. 76, H. 8, Suppl. 3 , S20-S27.

2008

Mehling, M. and Brinkmann, V. and Antel, J. and Bar-Or, A. and Goebels, N. and Vedrine, C. and Kristofic, C. and Kuhle, J. and Lindberg, R. L. and Kappos, L.. (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology, Vol. 71, H. 16. pp. 1261-1267.